Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction
Study Details
Study Description
Brief Summary
The investigators hypothesized that complementary intracoronary streptokinase administration to primary percutaneous intervention in patients with acute myocardial infarction may provide further improvement in myocardial perfusion by dissolving microvascular thrombus [in situ formed or embolized from proximal site (spontaneous or following PCI)] and fibrin.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Mechanical reperfusion for acute myocardial infarction (AMI) targets optimal revascularization of the epicardial artery but also aims at improved myocardial salvage. The goal of reperfusion therapies has shifted to include reperfusion downstream at the level of capillary bed, and it might be more appropriate that the hypothesis now be termed "the time dependent open artery and open microvascular hypothesis." Failure to achieve myocardial reperfusion despite the presence of a patent coronary artery has been termed the "no-reflow" phenomenon and attributed to microvascular dysfunction. It has become apparent that clinical outcomes are not only associated with patency of the epicardial artery, but also with patency of the microcirculation. Persistent impairment of microcirculation is associated with poor clinical outcome. Complete reperfusion in AMI settings necessitates reopening of the all consecutive vascular compartments all the way through the coronary circulation. But, embolization following percutaneous coronary intervention (PCI) and in situ microthrombi generation at the microvascular level makes this goal difficult to achieve. For this reason, mechanical intervention to the epicardial coronary artery with or without using distal protection wouldn't be enough to achieve ideal reperfusion at the ultimate (microvascular) level. At this point, it has become more evident that we need to develop more competent and feasible reperfusion strategies which can help us to achieve reperfusion as complete as possible at all levels.
Hypothesis:
Complementary intracoronary streptokinase administration to primary PCI may provide further improvement in myocardial perfusion by dissolving microvascular thrombus [in situ formed or embolized from proximal site (spontaneous or following PCI)] and fibrin. Improvement in microvascular perfusion may translate into reduction in infarct size and improvement in left ventricular function at long term.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given |
Drug: intracoronary infusion,
streptokinase, 250,000 units
Other Names:
Procedure: primary percutaneous coronary angioplasty
|
| Active Comparator: 2 Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed |
Procedure: primary percutaneous coronary angioplasty
|
Outcome Measures
Primary Outcome Measures
- Primary end points defined as the indices of the microvascular perfusion which is going to be assessed on day 2 (48 hours after the primary PCI)and infarct size at 6 months. [6 months]
- Index of microvascular resistance, [48 hours]
- Coronary flow reserve [48 hours]
- Left ventricular infarct size by SPECT at six months. [6 months]
Secondary Outcome Measures
- Death [1 year]
- Reinfarction [1 month]
- Major bleeding [during hospitalization]
Eligibility Criteria
Criteria
Inclusion criteria:
-
Continuous chest pain that lasted > 30 minutes within the preceding 12 hours
-
ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG
-
Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography
-
Angiographically detected culprit coronary artery lesion deemed suitable for PCI
Exclusion Criteria:
-
Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin
-
Culprit lesion in saphenous vein graft
-
TIMI grade II-III flow in IRA
-
Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)
-
Presence of left bundle branch block
-
History of prior MI
-
Mechanical ventilation or inotropic support
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Istanbul University, Istanbul School of Medicine, Department of Cardiology | Istanbul | Turkey | 34290 |
Sponsors and Collaborators
- Istanbul University
Investigators
- Study Director: Murat Sezer, M.D., Istanbul University, Istanbul School of Medicine
- Principal Investigator: Sabahattin Umman, Prof., Istanbul University, Istanbul School of Medicine
- Study Chair: Taner Goren, Prof., Istanbul University, Istanbul School of Medicine
- Study Chair: Huseyin Oflaz, Assoc.Prof., Istanbul University, Istanbul School of Medicine
- Study Chair: Irem Okcular, M.D., Istanbul University, Istanbul School of Medicine
- Study Chair: Yılmaz Nisanci, Prof., Istanbul University, Istanbul School of Medicine
- Study Chair: Berrin Umman, Prof., Istanbul University, Istanbul School of Medicine
- Study Chair: Ahmet K Bilge, M.D., Istanbul University, Istanbul School of Medicine
- Study Chair: Mehmet Meric, Prof., Istanbul University, Istanbul School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 5737